Stock Alert: Argenx Shares Up 30% On Topline Data From Phase 3 ADAPT Trial Of Efgartigimod

Shares of argenx (ARGX) are rising over 30% in pre-market today, after the global immunology company announced positive topline data from the pivotal ADAPT trial of efgartigimod.

from RTT - Before the Bell https://ift.tt/3eczZrQ
via IFTTT